Registration number:
Bio Swiss Ltd
for the Period from 16 December 2022 to 31 December 2023
Bio Swiss Ltd
Director's Report for the Period from 16 December 2022 to 31 December 2023
The director presents his report and the financial statements for the period from 16 December 2022 to 31 December 2023.
Incorporation
The company was incorporated on
Director of the company
The director who held office during the period was as follows:
Financial instruments
Objectives and policies
Click here to enter data
Price risk, credit risk, liquidity risk and cash flow risk
Click here to enter data
Small companies provision statement
This report has been prepared in accordance with the small companies regime under the Companies Act 2006.
Approved and authorised by the
......................................... |
Bio Swiss Ltd
Profit and Loss Account for the Period from 16 December 2022 to 31 December 2023
The company has not traded during the period. During this period, the company received no income and incurred no expenditure and therefore made neither profit nor loss.
Bio Swiss Ltd
(Registration number: 14544393)
Balance Sheet as at 31 December 2023
2023 |
|
Capital and reserves |
|
Shareholders' funds/(deficit) |
- |
For the financial period ending 31 December 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
Director's responsibilities:
• |
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
Approved and authorised by the
......................................... |
Bio Swiss Ltd
Notes to the Unaudited Financial Statements for the Period from 16 December 2022 to 31 December 2023
General information |
The company is a private company limited by share capital, incorporated in United Kingdom.
The address of its registered office is:
These financial statements were authorised for issue by the
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Going concern
The financial statements have been prepared on a going concern basis.
Staff numbers |
The average number of persons employed by the company (including the director) during the period, analysed by category was as follows:
2023 |
|
Other departments |
|
|
Share capital |
Allotted, called up and fully paid shares
Bio Swiss Ltd
Notes to the Unaudited Financial Statements for the Period from 16 December 2022 to 31 December 2023 (continued)
4 |
Share capital (continued) |
2023 |
||
No. |
£ |
|
|
|
100 |
Bio Swiss Ltd
iXBRL Detailed Profit and Loss Account for the Period from 16 December 2022 to 31 December 2023
Cost of sales |
Opening stock/inventories |
Closing stock/inventories |
Gross profit/(loss) |
Distribution costs |
Administrative expenses |
Other operating income |
Other items |
Profit/(loss) for the financial period |